[go: up one dir, main page]

MX2019009295A - Receptores de antigenos quimericos y metodos de realizacion. - Google Patents

Receptores de antigenos quimericos y metodos de realizacion.

Info

Publication number
MX2019009295A
MX2019009295A MX2019009295A MX2019009295A MX2019009295A MX 2019009295 A MX2019009295 A MX 2019009295A MX 2019009295 A MX2019009295 A MX 2019009295A MX 2019009295 A MX2019009295 A MX 2019009295A MX 2019009295 A MX2019009295 A MX 2019009295A
Authority
MX
Mexico
Prior art keywords
methods
chemeric
realization
antigens receptors
receptors
Prior art date
Application number
MX2019009295A
Other languages
English (en)
Inventor
J N Cooper Laurence
Beatriz Korngold Ana
A Rabinovich Brian
Singh Harjeet
Olivares Simon
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2019009295A publication Critical patent/MX2019009295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

Se proporcionan métodos para generar receptores de antígenos quiméricos (CAR). En algunas modalidades, la clasificación de la genoteca de CAR se realiza generando un vector que codifica el CAR a partir de unión aleatoria de vectores de genotecas de vectores que codifican dominios de unión al antígeno (p. ej., regiones de scFv), regiones de bisagra y endodominios. En algunas modalidades, los vectores contienen un transposón.
MX2019009295A 2014-02-14 2016-08-12 Receptores de antigenos quimericos y metodos de realizacion. MX2019009295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461940339P 2014-02-14 2014-02-14

Publications (1)

Publication Number Publication Date
MX2019009295A true MX2019009295A (es) 2019-12-02

Family

ID=53800695

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010566A MX369513B (es) 2014-02-14 2015-02-16 Receptores de antígenos quiméricos y métodos de realización.
MX2019009295A MX2019009295A (es) 2014-02-14 2016-08-12 Receptores de antigenos quimericos y metodos de realizacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016010566A MX369513B (es) 2014-02-14 2015-02-16 Receptores de antígenos quiméricos y métodos de realización.

Country Status (15)

Country Link
US (4) US10125193B2 (es)
EP (2) EP3656864A1 (es)
JP (2) JP6640726B2 (es)
KR (1) KR102375998B1 (es)
CN (2) CN106414748B (es)
AU (2) AU2015218239B2 (es)
CA (2) CA3190002A1 (es)
DK (1) DK3105335T3 (es)
ES (1) ES2764471T3 (es)
IL (3) IL247208B (es)
MX (2) MX369513B (es)
RU (2) RU2021123419A (es)
SG (2) SG10201811816RA (es)
WO (1) WO2015123642A1 (es)
ZA (2) ZA201605655B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US9629877B2 (en) 2013-05-14 2017-04-25 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
RU2021123419A (ru) * 2014-02-14 2021-10-22 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Химерные антигенные рецепторы и способы их получения
NZ739448A (en) 2014-04-10 2019-10-25 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Transgene genetic tags and methods of use
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
JP6947647B2 (ja) 2015-02-24 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 遺伝子改変ｔ細胞の選択方法
AU2016222887B2 (en) 2015-02-24 2022-07-14 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
DK3268470T3 (da) 2015-03-11 2021-02-22 Univ Texas Transposasepolypeptider og anvendelser deraf
WO2016149254A1 (en) 2015-03-17 2016-09-22 Chimera Bioengineering, Inc. Smart car devices, de car polypeptides, side cars and uses thereof
PL3291835T3 (pl) * 2015-04-23 2025-01-07 Baylor College Of Medicine Podzbiór komórek nkt do oceny trwałości i aktywności terapeutycznej in vivo oraz ich namnażanie
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
US11116795B2 (en) * 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
IL293963A (en) 2015-09-01 2022-08-01 Univ California Modular polypeptide libraries and methods of making and using same
AU2016323153B2 (en) 2015-09-15 2021-04-22 Board Of Regents, The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
US11400116B2 (en) 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells
EP3458077A4 (en) 2016-05-17 2020-04-01 Chimera Bioengineering Inc. METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
CN106167527A (zh) * 2016-06-13 2016-11-30 长沙郝怡雅医药科技有限公司 一种融合蛋白
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
SG10201913583QA (en) 2016-08-23 2020-02-27 Univ California Proteolytically cleavable chimeric polypeptides and methods of use thereof
WO2018045177A1 (en) 2016-09-01 2018-03-08 Chimera Bioengineering, Inc. Gold optimized car t-cells
AU2017335634A1 (en) * 2016-09-27 2019-03-14 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
CN107177632B (zh) * 2017-05-27 2020-02-07 上海优卡迪生物医药科技有限公司 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用
WO2018226897A1 (en) 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
CN109337872B (zh) * 2017-07-27 2023-06-23 上海细胞治疗研究院 高效扩增car-t细胞的人工抗原递呈细胞及其用途
CN107529550A (zh) * 2017-08-28 2018-01-02 马晓冬 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法
WO2019051424A2 (en) * 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
CN111936510B (zh) * 2017-09-15 2024-09-27 莱蒂恩技术公司 用于用抗cd19免疫治疗来治疗癌症的组合物和方法
AU2018341244A1 (en) * 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
CR20200170A (es) * 2017-09-29 2020-11-23 Us Health Receptores de células t que reconocen p53 mutado
WO2019079486A1 (en) * 2017-10-18 2019-04-25 Intrexon Corporation POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS
US10329543B2 (en) * 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
KR20200094147A (ko) * 2017-10-31 2020-08-06 알로젠 테라퓨틱스 인코포레이티드 동종이계 키메라 항원 수용체 t 세포를 투여하기 위한 방법 및 조성물
US10428141B2 (en) * 2017-11-03 2019-10-01 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
KR20250048610A (ko) 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
CN109970864A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 一种双向激活共刺激分子受体及其用途
CN111867619A (zh) 2018-01-03 2020-10-30 曲生物制品公司 过继性细胞治疗的先天寻靶
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US11110125B2 (en) 2018-02-13 2021-09-07 Chimera Bioengineering, Inc. Coordinating gene expression using RNA destabilizing elements
US20210017248A1 (en) * 2018-03-16 2021-01-21 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
CA3093973A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
EP3774906A1 (en) * 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
JP7575271B2 (ja) 2018-03-29 2024-10-29 フェイト セラピューティクス，インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CN110577605A (zh) * 2018-06-11 2019-12-17 浙江启新生物技术有限公司 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
MX2021006194A (es) 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
CN111253487B (zh) * 2018-12-03 2024-02-02 广东东阳光药业股份有限公司 Cd19抗体及其应用
JP7386382B2 (ja) 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US20200325241A1 (en) * 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Novel chimeric antigen receptors and libraries
US20210046117A1 (en) 2019-08-18 2021-02-18 Chimera Bioengineering, Inc. Combination Therapy with Gold Controlled Transgenes
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
GB201915384D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Vector
CN111304244A (zh) * 2019-11-13 2020-06-19 沣潮医药科技（上海）有限公司 携带基因元件组合的载体组件、受体细胞文库、制备和筛选方法及用途
CN110964750A (zh) * 2019-11-13 2020-04-07 沣潮医药科技（上海）有限公司 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途
KR20220130158A (ko) 2020-01-23 2022-09-26 더 칠드런스 메디칼 센터 코포레이션 인간 만능 줄기 세포로부터의 무-간질 t 세포 분화
CA3173673A1 (en) 2020-04-23 2021-10-28 The Regents Of The University Of California Genetically engineered phagocytes, and related compositions, vectors, methods and systems
BR112022024027A2 (pt) 2020-05-27 2023-02-07 Antion Biosciences Sa Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
EP4168538A4 (en) 2020-06-19 2024-03-20 Fate Therapeutics, Inc. COMBINATION OF IPSC-DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE
CN113913458A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 非病毒方法制备稳定高表达嵌合受体的nk细胞
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技（上海）有限公司 用于病原体清除的嵌合抗原受体及其应用
WO2022157500A1 (en) 2021-01-20 2022-07-28 Coding Bio Limited Methods for high throughput screening of chimeric antigen receptors
US20240197881A1 (en) * 2021-04-23 2024-06-20 Sorrento Therapeutics, Inc. Dimeric Antigen Receptors (DARs) that Bind GD2
GB2623653A (en) 2021-05-11 2024-04-24 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2023150672A1 (en) * 2022-02-04 2023-08-10 Duke University Compositions for and methods of treating hematological cancers
US20250135002A1 (en) * 2022-02-04 2025-05-01 Duke University Compositions for and method of effecting tumor cell death
CA3247423A1 (en) 2022-04-08 2023-10-12 Fate Therapeutics, Inc. CELLS WITH A SOLID TUMOR-TARGETING SKELETON AND THEIR USE
US20250222029A1 (en) 2022-04-08 2025-07-10 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
JPWO2024150828A1 (es) * 2023-01-12 2024-07-18

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
ATE240119T1 (de) 1995-03-08 2003-05-15 Scripps Research Inst Antigen präsentierendes system und aktivierung von t-zellen
AU723355B2 (en) 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
CA2280997C (en) 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
AU6869198A (en) 1997-03-25 1998-10-20 Morphogenesis, Inc. Universal stem cells
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
JP5312721B2 (ja) * 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1392818A4 (en) 2001-04-30 2005-01-05 Hope City FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR
AU2002338064A1 (en) 2002-02-05 2003-09-02 Japan Science And Technology Agency Egf/egfr complex
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1590485A2 (en) 2003-01-30 2005-11-02 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005019420A2 (en) * 2003-08-20 2005-03-03 St. Jude Children's Research Hospital Chimeric receptors with disrupted dileucine motifs
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
ATE549398T1 (de) 2004-10-08 2012-03-15 Us Gov Health & Human Serv Adoptive immuntherapie mit erhöhter t-lymphozyten-lebensdauer
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
SG10201508995QA (en) 2005-07-26 2015-11-27 Sangamo Biosciences Inc Targeted integration and expression of exogenous nucleic acid sequences
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP1996232B1 (en) 2006-03-01 2016-04-06 Janssen Pharmaceutica N.V. CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
US20070283453A1 (en) 2006-05-31 2007-12-06 Juan Carlos Rodriguez Cimadevilla Animal models of tumor metastasis and toxicity
RU2355763C2 (ru) 2006-09-13 2009-05-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
US8124408B2 (en) 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
CN101573380A (zh) * 2006-10-12 2009-11-04 健泰科生物技术公司 针对淋巴毒素-α的抗体
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
NZ616254A (en) 2007-06-27 2015-04-24 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US20100105140A1 (en) 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
US8945868B2 (en) 2010-07-21 2015-02-03 Sangamo Biosciences, Inc. Methods and compositions for modification of a HLA locus
ES2651170T3 (es) 2010-09-21 2018-01-24 Altor Bioscience Corporation Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
AU2012308205A1 (en) 2011-09-16 2014-03-13 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
US9708384B2 (en) * 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
RU2644243C2 (ru) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы к cd22
US9272002B2 (en) * 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
SG11201404285VA (en) * 2012-02-22 2014-10-30 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
SG11201404769UA (en) * 2012-02-22 2014-11-27 Univ Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
EP2836239A1 (en) 2012-04-11 2015-02-18 The United States of America, as Represented By the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP2855666B1 (en) * 2012-05-25 2019-12-04 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US9719066B2 (en) 2012-09-07 2017-08-01 Biolamina Ab Stem cell bank
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
HK1220614A1 (zh) 2013-03-10 2017-05-12 Baylor College Of Medicine 耐化疗免疫细胞
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
US9629877B2 (en) * 2013-05-14 2017-04-25 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
WO2015061694A2 (en) 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
RU2021123419A (ru) 2014-02-14 2021-10-22 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Химерные антигенные рецепторы и способы их получения
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
WO2015164594A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
KR20200138445A (ko) 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
EP3174974B1 (en) 2014-07-29 2020-05-20 Novartis AG Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP6947647B2 (ja) 2015-02-24 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 遺伝子改変ｔ細胞の選択方法
DK3268470T3 (da) 2015-03-11 2021-02-22 Univ Texas Transposasepolypeptider og anvendelser deraf
AU2016323153B2 (en) 2015-09-15 2021-04-22 Board Of Regents, The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
AU2016326575A1 (en) 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US20190117690A1 (en) 2016-04-06 2019-04-25 The University State Of America As Represented By The Secretary Of The Department Of Health And Hum Use of heterodimeric il-15 in adoptive cell transfer
WO2018132494A1 (en) * 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems

Also Published As

Publication number Publication date
CA3190002A1 (en) 2015-08-20
CN106414748A (zh) 2017-02-15
AU2015218239A1 (en) 2016-08-18
MX369513B (es) 2019-11-11
IL281819A (en) 2021-05-31
EP3656864A1 (en) 2020-05-27
US20190085079A1 (en) 2019-03-21
CN113234757B (zh) 2024-10-29
US20210324071A1 (en) 2021-10-21
DK3105335T3 (da) 2020-01-13
CN113234757A (zh) 2021-08-10
WO2015123642A1 (en) 2015-08-20
ES2764471T3 (es) 2020-06-03
EP3105335A1 (en) 2016-12-21
RU2753965C2 (ru) 2021-08-24
SG11201606664UA (en) 2016-09-29
AU2019202514A1 (en) 2019-05-02
AU2019202514B2 (en) 2022-03-24
IL272264A (en) 2020-02-27
US20250002579A1 (en) 2025-01-02
AU2015218239B2 (en) 2019-01-31
IL281819B2 (en) 2023-05-01
EP3105335B1 (en) 2019-10-02
MX2016010566A (es) 2017-05-25
IL247208A0 (en) 2016-09-29
ZA201807750B (en) 2024-10-30
ZA201605655B (en) 2019-03-27
CA2938887C (en) 2023-04-11
IL247208B (en) 2020-02-27
IL281819B1 (en) 2023-01-01
EP3105335A4 (en) 2017-12-27
JP6640726B2 (ja) 2020-02-05
IL272264B (en) 2021-04-29
RU2016136370A3 (es) 2019-02-21
RU2016136370A (ru) 2018-09-05
KR102375998B1 (ko) 2022-03-21
US20170183407A1 (en) 2017-06-29
US12065490B2 (en) 2024-08-20
SG10201811816RA (en) 2019-02-27
JP2017506513A (ja) 2017-03-09
KR20160120307A (ko) 2016-10-17
US10125193B2 (en) 2018-11-13
CN106414748B (zh) 2021-05-28
RU2021123419A (ru) 2021-10-22
CA2938887A1 (en) 2015-08-20
JP2020058380A (ja) 2020-04-16

Similar Documents

Publication Publication Date Title
MX2019009295A (es) Receptores de antigenos quimericos y metodos de realizacion.
AR120262A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
MX2021008652A (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2017009182A (es) Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.
MX390385B (es) Anticuerpos anti-pd-l1.
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
EP3474867A4 (en) CHIMEAN ANTIGENT RECEPTORS (CARS) COMPOSITIONS AND METHODS FOR USE THEREOF
CO2017006808A2 (es) Receptores de antígenos quiméricos de bcma
UY36245A (es) Constructos de anticuerpos para cdh19 y cd3
AR081750A1 (es) Anticuerpos anti-cd40
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
MX2020003497A (es) Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids
MX2021009744A (es) Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados.
MX2015007459A (es) Metodo de generacion de vectores de inmunizacion para acelerar la respuesta inmune.
AR121984A2 (es) Métodos de preparación de células que expresan receptores de antígenos quiméricos